
IDC Perspective: How Technology Is Driving Diversity and Equity in Clinical Trials
Description
IDC Perspective: How Technology Is Driving Diversity and Equity in Clinical Trials
This IDC Perspective reviews the existing landscape and critical challenges associated with driving diversity and equity in clinical trials. It reviews strategies that pharma is using to address these challenges and scans the evolving technology landscape that is playing a critical role in driving change. It also examines regulatory policies and guidances, identifies the key measures of success, and provides guidance on implementing a diversity strategy."Inclusive clinical development is a must to address the deep-rooted disparities that prevail across the globe. There is no silver bullet to address this issue. It requires a focused, sustained, and collaborative effort; it requires sensitivity and empathy to be woven into technology and strategy; and it calls for a genuine deep-seated commitment toward driving inclusiveness and equity in clinical trials," says Dr. Nimita Limaye, research vice president, Life Sciences R&D Strategy and Technology at IDC Health Insights.
Please Note: Extended description available upon request.
This IDC Perspective reviews the existing landscape and critical challenges associated with driving diversity and equity in clinical trials. It reviews strategies that pharma is using to address these challenges and scans the evolving technology landscape that is playing a critical role in driving change. It also examines regulatory policies and guidances, identifies the key measures of success, and provides guidance on implementing a diversity strategy."Inclusive clinical development is a must to address the deep-rooted disparities that prevail across the globe. There is no silver bullet to address this issue. It requires a focused, sustained, and collaborative effort; it requires sensitivity and empathy to be woven into technology and strategy; and it calls for a genuine deep-seated commitment toward driving inclusiveness and equity in clinical trials," says Dr. Nimita Limaye, research vice president, Life Sciences R&D Strategy and Technology at IDC Health Insights.
Please Note: Extended description available upon request.
Table of Contents
12 Pages
- Executive Snapshot
- Situation Overview
- The Current Scenario
- Where Do the Challenges Lie?
- Evolving Regulations That Are Impacting D&I in Clinical Trials
- Integrating Diversity into Approval Decisions for Oncology Studies
- Strategies Leveraged by Pharma to Increase Diversity in Clinical Trials
- Key Players Providing D&I Solutions
- Identifying Measures of Success
- Advice for the Technology Buyer
- Learn More
- Related Research
- Synopsis
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.